Nguyen T. Huong, Nguyen T. N. Hoi, Mac D. Hung, Le M. Tri, Nguyen V. Hung, Le D. Anh, Vu T. Dong, Ly Q. Vuong, Vu M. Thanh
{"title":"A redox-responsive delivery system for paclitaxel based on heparin—pluronic F127 nanogel","authors":"Nguyen T. Huong, Nguyen T. N. Hoi, Mac D. Hung, Le M. Tri, Nguyen V. Hung, Le D. Anh, Vu T. Dong, Ly Q. Vuong, Vu M. Thanh","doi":"10.1007/s11051-023-05841-z","DOIUrl":null,"url":null,"abstract":"<div><p>Paclitaxel (PTX), a chemo-drug widely used in cancer chemotherapy for a variety of tumors, has been still faced with several problems in therapeutic applications due to its poor water solubility, low content in natural sources, expensive multistep processes of synthesis and side effects. In this study, a nanogel system based on the conjugation of Heparin and Pluronic F127 via disulphide bridges was developed for PTX delivery in a redox responsive way to over these mentioned drawbacks. The obtained Hep-F127 system were proved and characterized through H-NMR, zeta potential, DLS, TEM and FT-IR methods. TEM result showed that the nanogel Hep-F127 was spherical, non-agglomerated and relatively uniform with an average particle diameter of 80 nm. PTX was effectively encapsulated into the nanogel thanks to poly(propylene oxide) (PPO) units of F127 molecules with DLE and DLC values of about 92% and 18%, respectively. Meanwhile, the nanogel was stable in physiological condition but broken under reducing condition, leading to a well-controlled release in physiological condition and a fast release in simulating tumor-microenvironmental condition. This contributed to reducing side effects and increasing the effectiveness of treatment of PTX. In addition, cytotoxicity of Hep-F127 and PTX@Hep-F127 was in vitro tested on the L929 cell line. This study suggested that the nanogel Hep-F127 would to be a promising carrier for enhancing the solubility of PTX and release PTX in a redox-responsive way in cancer treatment.</p></div>","PeriodicalId":653,"journal":{"name":"Journal of Nanoparticle Research","volume":"25 9","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nanoparticle Research","FirstCategoryId":"88","ListUrlMain":"https://link.springer.com/article/10.1007/s11051-023-05841-z","RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Paclitaxel (PTX), a chemo-drug widely used in cancer chemotherapy for a variety of tumors, has been still faced with several problems in therapeutic applications due to its poor water solubility, low content in natural sources, expensive multistep processes of synthesis and side effects. In this study, a nanogel system based on the conjugation of Heparin and Pluronic F127 via disulphide bridges was developed for PTX delivery in a redox responsive way to over these mentioned drawbacks. The obtained Hep-F127 system were proved and characterized through H-NMR, zeta potential, DLS, TEM and FT-IR methods. TEM result showed that the nanogel Hep-F127 was spherical, non-agglomerated and relatively uniform with an average particle diameter of 80 nm. PTX was effectively encapsulated into the nanogel thanks to poly(propylene oxide) (PPO) units of F127 molecules with DLE and DLC values of about 92% and 18%, respectively. Meanwhile, the nanogel was stable in physiological condition but broken under reducing condition, leading to a well-controlled release in physiological condition and a fast release in simulating tumor-microenvironmental condition. This contributed to reducing side effects and increasing the effectiveness of treatment of PTX. In addition, cytotoxicity of Hep-F127 and PTX@Hep-F127 was in vitro tested on the L929 cell line. This study suggested that the nanogel Hep-F127 would to be a promising carrier for enhancing the solubility of PTX and release PTX in a redox-responsive way in cancer treatment.
期刊介绍：
The objective of the Journal of Nanoparticle Research is to disseminate knowledge of the physical, chemical and biological phenomena and processes in structures that have at least one lengthscale ranging from molecular to approximately 100 nm (or submicron in some situations), and exhibit improved and novel properties that are a direct result of their small size.
Nanoparticle research is a key component of nanoscience, nanoengineering and nanotechnology.
The focus of the Journal is on the specific concepts, properties, phenomena, and processes related to particles, tubes, layers, macromolecules, clusters and other finite structures of the nanoscale size range. Synthesis, assembly, transport, reactivity, and stability of such structures are considered. Development of in-situ and ex-situ instrumentation for characterization of nanoparticles and their interfaces should be based on new principles for probing properties and phenomena not well understood at the nanometer scale. Modeling and simulation may include atom-based quantum mechanics; molecular dynamics; single-particle, multi-body and continuum based models; fractals; other methods suitable for modeling particle synthesis, assembling and interaction processes. Realization and application of systems, structures and devices with novel functions obtained via precursor nanoparticles is emphasized. Approaches may include gas-, liquid-, solid-, and vacuum-based processes, size reduction, chemical- and bio-self assembly. Contributions include utilization of nanoparticle systems for enhancing a phenomenon or process and particle assembling into hierarchical structures, as well as formulation and the administration of drugs. Synergistic approaches originating from different disciplines and technologies, and interaction between the research providers and users in this field, are encouraged.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
